Iclusig ponatinib regulatory update

Ariad said Health Canada approved Iclusig ponatinib under the agency’s Notice of Compliance with Conditions policy to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The pan- BCR-ABL tyrosine kinase inhibitor (TKI) is indicated in patients for whom other TKI therapy is not appropriate, including CML or Ph+ ALL that has the T315I variant of BCR-ABL tyrosine kinase, or where there is prior TKI resistance or intolerance. ...